Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial aims to ease daily life for myasthenia gravis patients

NCT ID NCT06967480

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug ravulizumab can improve daily activities in people with early-stage generalized myasthenia gravis who have a specific antibody (AChR-positive). About 40 participants will receive treatment and be followed for 50 weeks. The main goal is to see if symptoms like muscle weakness get better, helping with tasks like talking, chewing, and breathing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with anti-AChR antibody positive, generalized, myasthenia gravis elegible to Ravulizumab treatment with a disease duration from onset equal or less than 3 years.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of MG confirmed by: * History of a positive serologic test for anti-AChR antibodies, and * One of the following: * History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation * History of positive anticholinesterase test (e.g., edrophonium chloride test); or * Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician * Disease duration from MG onset ≤ 3 years before T-4 (Enrolment); * MGFA class IIb to IV; * Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria * Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC. Exclusion Criteria: * Patient unable to understand and sign the informed consent * Hypersensitivity to the active substance or to any of the excipients of the study product * Patient for whom the study product is contraindicated according to SmPC * Previous treatment with C5 inhibitors * Last rituximab infusion performed \< 6 months before T-4 (Enrolment) * Last infusion with FcRn blockers performed \< 3 months before T-4 (Enrollment) * Pregnant or lactating or planning a pregnancy during the study * Patient who plan to relocate during the study * Patient who are unsure of following the visit schedule * Patient unable to complete questionnaires * Previous or current participation to other interventional studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anti-achr antibody positive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anti-achr antibody positive Generalized myasthenia gravis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    23 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Clinical Trial Site

    RECRUITING

    Bergamo, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Bologna, Italy

  • Clinical Trial Site

    RECRUITING

    Bologna, Italy

  • Clinical Trial Site

    RECRUITING

    Brescia, Italy

  • Clinical Trial Site

    RECRUITING

    Florence, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Imperia, Italy

  • Clinical Trial Site

    RECRUITING

    Lecco, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Messina, Italy

  • Clinical Trial Site

    RECRUITING

    Milan, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Milan, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Naples, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Novara, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Orbassano, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Padova, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Palermo, Italy

  • Clinical Trial Site

    RECRUITING

    Parma, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Pavia, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Pisa, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Roma, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Salerno, Italy

  • Clinical Trial Site

    RECRUITING

    San Giovanni Rotondo, 71013, Italy

  • Clinical Trial Site

    RECRUITING

    Sassari, Italy

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Torino, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.